Biocon Biologics to buy biosimilars business of Viatris for up to $3.3bn

pallavi123- March 1, 2022 0

Biocon Biologics Limited (BBL), a subsidiary of Indian biopharma company Biocon, has agreed to acquire the biosimilars business of Viatris, a US-based pharma company, in ... Read More

Biocon ties-up with Tabuk to bring specialty generic products in Middle East

pallavi123- December 7, 2021 0

Indian pharma company Biocon Limited has forged a partnership with Tabuk Pharmaceutical Manufacturing Company to commercialize certain specialty generic medicines in the Middle East. Tabuk ... Read More

Biocon Biologics, Viatris launch interchangeable biosimilars in US

pallavi123- November 16, 2021 0

Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine ... Read More

Biocon to sell 15% stake in Biocon Biologics to Serum Institute of India

pallavi123- September 16, 2021 0

Biocon has agreed to divest a stake of around 15% in its subsidiary — Biocon Biologics Limited (BBL) to Serum Institute Life Sciences Private Limited ... Read More

Biocon gets license for Adagio Therapeutics’ ADG20 for Covid-19 treatment

pallavi123- July 26, 2021 0

Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing ... Read More

Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil

pallavi123- March 30, 2021 0

Biocon Ltd, an Indian biopharma company, has entered into a partnership with Brazilian pharma company Libbs Farmaceutica for launching generic drugs in Brazil. The company ... Read More

Biocon expands generics portfolio with Tacrolimus launch in US

pharmanewsdaily- December 30, 2020 0

Biocon, the prominent Indian biopharmaceutical company, has made a significant leap in the US pharmaceutical market with the launch of its generic Tacrolimus capsules. This ... Read More